Archive | December, 2017

Over 400 Qualified Life Science Investors Registered For Redefining Early Stage Investments (RESI) Conference at JP Morgan, Jan 9th at Marine Memorial Hotel, Union Square

28 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

RESI is different, in that, the LSN research team actually qualifies all the investors that attend the RESI conference. The LSN researchers, through one-on-one phone conversations, validate that all the investors have current or future mandates to invest in early stage technology assets across the domains of drugs, devices, diagnostics or healthcare IT. Fundraising CEOs and scientist entrepreneur’s don’t have to guess who they are meeting with on the other side of the table. As a matter of fact, we kindly ask the I-banks, broker dealers and debt providers to sign up as service providers so the fundraisers know who’s who in the whirlwind of meetings taking place at RESI. This will be our fourth RESI @ JPM and we expect to close down registrations due to the capacity constraint on the Marine Memorial Hotel in Union Sq. The good news is we are still accepting registrations “click here to register”.

RESI @ JPM will be the most compelling event LSN has held because the investor to fundraiser ratio will be 1-to-1, as amazing as that sounds. If you are a fundraising executive please take advantage of this opportunity to meet investors that are a fit for your stage of development and product set. RESI Partnering is now up and running with half of the meetings now booked. There is still time to dramatically impact the number of investors on your radar screen. Raising money is a numbers game, and RESI was created to help identify investors that are a fit, create a dialogue, and foster relationships that help you move towards allocations. Please scroll down and see the investors currently signed up for RESI at JPM.

Hot Investor Mandate 1: China-based Private Equity Firm Invests in Biopharma, Medical Devices and Equipment, Diagnostics, HCIT, and R&D Services

28 Dec

A China-based private equity firm with additional offices in Beijing, Shanghai, and Hong Kong with an affiliation to an established Silicon Valley-based investment firm has raised 10 funds to date. The firm invests across several sectors including healthcare. The firm is a full-spectrum investor and will invest from Series A to pre-IPO and PIPE. The firm may also consider buyout and add-on acquisition for its portfolio companies. The firm can invest up to US$100 million per company. Typical investments range from US$5-50 millions. In terms of geography, the firm is China focused, but is also interested in opportunities from US and Europe with a strong China angle.

The firm invests opportunistically in the Healthcare sector and considers each deal on a case-by-case basis. Sectors of interest include biopharma, medical devices and equipment, diagnostics, HCIT, and R&D services that have large market potential. The firm is agnostic to the stage of development. The firm will consider products in pre-clinical up to market approved products.

The firm invests in both private and public companies. The firm invests in Chinese companies as well as US- and Europe-based companies with a China angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Japanese Pharmaceutical Company Seeking Global Collaboration and In-licensing Opportunities

28 Dec

A global pharmaceutical company headquartered in Japan, with USA operations, is actively seeking global collaboration and in-licensing opportunities within the early-stage ecosystem to strengthen their pipeline.

The company is seeking innovative therapies with highest focus on the following: CNS diseases, autoimmune diseases, and diabetes/kidney diseases. The company’s pipeline covers other indications as well and the company may review such opportunities on a case-by-case basis. The company is open to all stages of development, and those who have passed PoC are considered most ideal. The company has a strong interest in excellent technologies in biologics, including therapeutic antibodies, vaccines, and nucleic acid drugs, as well as cell-based phenotypic screening models of CNS or skeletal muscle diseases for new drug discovery.

Currently, the company’s main research focus can be broken down into 3 main branches: (1) nucleic acid medicine, (2) vaccines, and (3) macrocyclic compounds. In terms of their first interest, the company is highly interested in novel nucleic acid delivery systems targeted CNS and skeletal muscle, particularly those that could enable successful delivery from the gut. In terms of vaccines, the company is looking for innovative vaccine platforms to strengthen their current pipeline, which targets a broad range of infectious diseases. The last area of interest involves macrocyclic compounds with peptide modifications that could increase their cell permeability and therapeutic potential.

The company seeks to work with management teams with strong scientific expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: